Paratek Pharmaceuticals, Inc. (PRTK)
| Market Cap | 200.25M |
| Revenue (ttm) | 114.39M |
| Net Income (ttm) | -51.84M |
| Shares Out | 50.19M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | 15.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 398,520 |
| Open | 4.08 |
| Previous Close | 4.09 |
| Day's Range | 3.90 - 4.10 |
| 52-Week Range | 3.90 - 11.24 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 21.50 (+438.8%) |
| Earnings Date | Feb 22, 2022 |
About PRTK
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PRTK stock is "Strong Buy." The 12-month stock price forecast is 21.50, which is an increase of 438.85% from the latest price.
News
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneum...
Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business a lone , a 30% Increase over Prior Quarter
Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30...
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for...
-- Potential $1 Billion Addressable Market Opportunity in the United States -- Potential $1 Billion Addressable Market Opportunity in the United States
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project BioShield contract. Related Link: Paratek's Antibio...
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (...
-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infec...
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection
The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM). The orphan drug designatio...
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infecti...
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Paratek Pharmaceuticals (PRTK) Q2 Earnings and Revenues Miss Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals: Q2 Earnings Insights
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74% over the past year to $0.20, wh...
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter
Paratek Stock Is Trading Higher As CDC Adds Nuzyra As Recommended Antibiotic For Plague Treatment
The Center for Disease Control and Prevention (CDC) has added Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) antibiotic Nuzyra (omadacycline) as an alternative agent for pre-exposure prophylaxis and poste...
Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatmen...
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Paratek Pharmaceuticals (PRTK) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...
Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 ...
-- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021 -- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management